Sponsors (28)
The bill strongly expands nationwide patient access to FDA‑approved medicines and protects provider speech and assistance, but in doing so it significantly curtails state regulatory authority and raises litigation, liability, and potential public‑cost and safety trade‑offs.
Patients nationwide (including people with chronic conditions, uninsured individuals, and seniors) can obtain FDA‑approved medicines across state lines without being blocked by state or local bans.
Health care providers (doctors, nurses, pharmacists, clinics, hospitals) receive statutory protections to discuss, prescribe, refer, and assist patients with FDA‑approved medicines, reducing legal risk for clinical counseling and care delivery.
Providers, helpers, and entities can raise the Act as a defense and prevailing plaintiffs can recover attorney fees, lowering financial barriers for lawsuits that restore access and deterring unlawful restrictions.
States and localities lose substantial authority to restrict or tailor regulation of certain medicines (e.g., bans, age limits, dispensing controls), reducing local public‑health flexibility.
The bill creates substantial new litigation risk and costs for states, localities, payers, providers, and taxpayers as parties contest preemption, enforcement, and the heightened evidentiary standards.
Broad access protections could increase use of FDA‑approved products in ways that raise costs for insurers and public programs (higher utilization, coverage claims), affecting premiums and public spending.
Based on analysis of 8 sections of legislative text.
Creates a federal right to obtain and prescribe FDA‑approved medicines, bars laws that single out or restrict such access, and allows federal and private lawsuits to enforce that right.
Introduced July 17, 2025 by Deborah K. Ross · Last progress July 17, 2025
Creates a federal right for individuals to obtain FDA‑approved drugs and for licensed health care providers to prescribe, provide information about, refer for, and otherwise facilitate access to those medicines without being singled out or blocked by state or federal laws. The measure preempts conflicting state and federal restrictions, permits the U.S. Attorney General and private parties to sue to block or remove laws and rules that impede access, and requires courts to award fees to prevailing plaintiffs while protecting nonfrivolous defendants from fee exposure. The bill defines key terms (FDA‑approved medicine, government, health care provider, State), preserves existing federal insurance and federal health program coverage rules, directs courts to interpret the law broadly to achieve access goals, and becomes effective immediately on enactment. It does not change how the FDA approves or licenses drugs and biologics.